Treatment options for newly diagnosed patients with chronic myeloid leukemia.

Lori J. Maness, Peter A. McSweeney

Research output: Contribution to journalReview article

8 Scopus citations

Abstract

Chronic myeloid leukemia (CML) is characterized by a 9:22 translocation resulting in production of a chimeric BCR-ABL fusion protein that has constitutive tyrosine kinase activity and drives leukemic transformation. Imatinib mesylate, a selective inhibitor of BCR-ABL, has been introduced into clinical trials with favorable toxicity and impressive activity at all disease stages. In a phase III study of diagnosed chronic phase CML, imatinib mesylate was superior to interferon plus cytarabine in cytogenetic response, freedom from disease progression, and tolerability. Hematopoietic stem cell transplantation remains the only established cure for CML. Recent reports show continued improvements with survivals after matched sibling grafts greater than 80% at 3 to 5 years. Therefore, recent advances in conventional and transplant therapy have improved treatment options for newly diagnosed patients. Sensitive and specific monitoring techniques developed for CML may help further refine treatment with regard to using these and other emerging therapies.

Original languageEnglish (US)
Pages (from-to)54-61
Number of pages8
JournalCurrent hematology reports
Volume3
Issue number1
StatePublished - Jan 2004

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Treatment options for newly diagnosed patients with chronic myeloid leukemia.'. Together they form a unique fingerprint.

  • Cite this